stockrowVir Biotechnology, Inc.
VIRVir Biotechnology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $68.6 million, down 7.61% from fiscal 2024.
- Revenue
- −178.3%
- EPS
- +51.4%
- Free cash flow
- +36.8%
Quarter to September 2026, against a year earlier
Follow VIR
Alert me
Vir Biotechnology, Inc. (VIR) EPS (diluted)
Vir Biotechnology, Inc.'s EPS (diluted) for fiscal 2025 was −$3.16, compared with −$3.83 in fiscal 2024. Over the twelve months to 30 September 2026 it was −$1.26. Over the past ten years it has ranged from −$32.46 (fiscal 2017) to $3.96 (fiscal 2021); the current reading is higher than 67% of that period. Vir Biotechnology, Inc. ranks 248th of 582 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$3.16 | — |
| FY2024 | −$3.83 | — |
| FY2023 | −$4.59 | — |
| FY2022 | $3.83 | (3.28%) |
| FY2021 | $3.96 | — |
| FY2020 | −$2.51 | — |
| FY2019 | −$5.76 | — |
| FY2018 | −$15.12 | — |
| FY2017 | −$32.46 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | −$0.57 | — |
| Jun 2026 | $0.47 | — |
| Mar 2026 | −$0.85 | — |
| Dec 2025 | −$0.31 | — |
| 28 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| ZYME Zymeworks Inc. compare | $0.52 |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | −$0.29 |
| RXRX Recursion Pharmaceuticals, Inc. compare | −$0.90 |
| VIR Vir Biotechnology, Inc. | −$1.26 |
| NAMS NewAmsterdam Pharma Company N.V. compare | −$1.69 |
| IMNM Immunome, Inc. compare | −$2.64 |
| REPL Replimune Group, Inc. compare | −$2.79 |
| BHVN Biohaven Ltd. compare | −$3.86 |
| TRAX First Tracks Biotherapeutics, Inc. compare | −$5.17 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on VIR
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement